Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Xu, Yan"'
Autor:
Yao Y; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Blood Disease Institute, Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, China., Ng JF; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Park WD; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX., Samur M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Morelli E; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Encinas Mayoral J; University Hospital October 12, Madrid, Spain., Chyra Z; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Xu Y; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Derebail S; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Epstein C; Broad Institute, Cambridge, MA., Nabet B; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA., Chesi M; Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ., Gray NS; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford Medical School, Stanford, CA., Young RA; Whitehead Institute for Biomedical Research, Cambridge, MA., Kwiatkowski N; Kymera Therapeutics, Watertown, MA., Mitsiades C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Anderson KC; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Lin CY; Kronos Bio, Cambridge, MA., Munshi NC; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA., Fulciniti M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Publikováno v:
Blood [Blood] 2023 Jun 08; Vol. 141 (23), pp. 2841-2852.
Autor:
Xu Y; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China., Fulciniti M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Samur MK; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Ho M; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; UCD Conway Institute of Biomolecular and Biomedical Science, UCD School of Medicine, University College Dublin, Belfield (UCD), Dublin, Ireland., Deng S; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China., Liu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China., Wen K; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Yu T; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China., Chyra Z; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Dereibal S; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Zhang L; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Hematology, West China Hospital, Sichuan University, Chengdu, China., Yao Y; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Blood Disease Institute, The Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, China., Chakraborty C; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Morelli E; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Li N; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Medical Oncology, The Second Affiliated Hospital of Dalian Medical University, Liaoning, China., Lopez MA; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Perini T; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; IRCCS Ospedale San Raffaele, Milano, Italy., Mu S; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; and., An G; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China., Alonso R; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Bianchi G; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Tai YT; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Anderson KC; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Qiu L; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China., Munshi NC; Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.
Publikováno v:
Blood [Blood] 2020 Jul 23; Vol. 136 (4), pp. 468-479.
Autor:
Zhang L; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.; Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL., Li J; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China., Xu H; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China., Shao X; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China., Fu L; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China., Hou Y; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China., Hao C; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China., Li W; Department of Gynaecology and Obstetrics, Lanzhou University Second Hospital, Lanzhou, China., Joshi K; Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL., Wei W; Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL., Xu Y; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China., Zhang F; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China., Dai S; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China., Breslin P; Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.; Department of Biology and.; Department of Cell and Molecular Physiology, Loyola University Chicago, Chicago, IL; and., Zhang J; Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL.; Department of Pathology, Loyola University Medical Center, Maywood, IL., Zhang J; Department of Biology, College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
Publikováno v:
Blood [Blood] 2020 Apr 02; Vol. 135 (14), pp. 1133-1145.
Autor:
Fulciniti M; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Martinez-Lopez J; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Hospital Universitario 12 de Octubre, Complutense School of Medicine, Spanish National Cancer Research Centre, Madrid, Spain., Senapedis W; Karyopharm Therapeutics Inc, Newton, MA., Oliva S; Myeloma Unit, Division of Hematology, University of Turin, Italy., Lakshmi Bandi R; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Amodio N; Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy., Xu Y; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Szalat R; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Gulla A; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Samur MK; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Roccaro A; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; CREA Laboratory, Department of Medical Oncology, ASST Spedali Civili di Brescia, Brescia, Italy., Linares M; Hospital Universitario 12 de Octubre, Complutense School of Medicine, Spanish National Cancer Research Centre, Madrid, Spain., Cea M; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Medicine (DiMI), University of Genoa, Italy., Baloglu E; Karyopharm Therapeutics Inc, Newton, MA., Argueta C; Karyopharm Therapeutics Inc, Newton, MA., Landesman Y; Karyopharm Therapeutics Inc, Newton, MA., Shacham S; Karyopharm Therapeutics Inc, Newton, MA., Liu S; Barnett Institute, Northeastern University, Boston, MA., Schenone M; Broad Institute, Cambridge, MA; and., Wu SL; Barnett Institute, Northeastern University, Boston, MA., Karger B; Barnett Institute, Northeastern University, Boston, MA., Prabhala R; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA., Anderson KC; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Munshi NC; LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.
Publikováno v:
Blood [Blood] 2017 Apr 20; Vol. 129 (16), pp. 2233-2245. Date of Electronic Publication: 2017 Jan 17.
Autor:
Zhang W; Department of Mechanical Engineering and Mechanics, Bioengineering Program, Lehigh University, Bethlehem, PA;, Deng W; Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA;, Zhou L; Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA;, Xu Y; Department of Mechanical Engineering and Mechanics, Bioengineering Program, Lehigh University, Bethlehem, PA;, Yang W; Department of Biochemistry and Molecular Biology, University of Texas Health Science Center at Houston, Houston, TX; and., Liang X; Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA;, Wang Y; Department of Mechanical Engineering and Mechanics, Bioengineering Program, Lehigh University, Bethlehem, PA;, Kulman JD; Puget Sound Blood Center, Seattle, WA., Zhang XF; Department of Mechanical Engineering and Mechanics, Bioengineering Program, Lehigh University, Bethlehem, PA;, Li R; Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA;
Publikováno v:
Blood [Blood] 2015 Jan 15; Vol. 125 (3), pp. 562-9. Date of Electronic Publication: 2014 Oct 30.